US Edition€225 Million Investment in Vaccines
7 Articles
7 Articles
The European Commission will ensure that the tests meet "the strict criteria for safety, quality and efficiency while supporting innovations which could take place without public intervention".
The European Commission is investing more than €200 million in the development of next-generation influenza vaccines. The funds will support the development of nasal, oral or skin-applied vaccines that can be produced quickly, in large quantities in an emergency and do not require a needle.
Commission envisages next-generation influenza vaccines
The European Union is investing €225 million to expedite the development of next-generation influenza vaccines. These vaccines are intended to offer protection against a broader range of influenza variants and can be rapidly adapted to emerging pandemic strains. This initiative marks the first time the European Commission will use pre-commercial procurement to advance products through clinical trials, ensuring they meet rigorous safety, quality,…
Protect against greater n mer of vrus variants.
The European Commission is investing 225 million euros to accelerate the development of new-generation influenza vaccines that can provide broader protection against different virus variants and can be quickly adapted in the event of a pandemic, the Brussels body announced on Friday.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
